


SARS-CoV-2-IN-33

Cat. No.:	HY-151478
CAS No.:	299919-79-2
Molecular Formula:	C ₃₀ H ₃₀ N ₄ O ₅
Molecular Weight:	526.58
Target:	SARS-CoV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SARS-CoV-2-IN-33 (compound 3m) is a COVID-19 inhibitor. SARS-CoV-2-IN-33 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-33 exhibits comparatively good binding affinity (-8.0 Kcal/mole) to COVID-19 main protease (M ^{Pro}) (PDB ID: 6LU7). SARS-CoV-2-IN-33 can be used in studies of cancer and COVID-19 ^[1] .								
IC₅₀ & Target	COVID-19 ^[1] .								
In Vitro	<p>SARS-CoV-2-IN-33 (0-40 μM) exhibits good antiproliferative activity in MCF-7, MDA-MB-231, HeLa and PC-3 cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MCF-7, MDA-MB-231, HeLa, PC-3, Ishikawa, HEK-293</td> </tr> <tr> <td>Concentration:</td> <td>0-40 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited proliferation of MCF-7, MDA-MB-231, HeLa, PC-3, Ishikawa, HEK-293 cells with IC₅₀ values of 5.45, 9.47, 22.86, 28.44, >40 and >40 μM, respectively.</td> </tr> </table>	Cell Line:	MCF-7, MDA-MB-231, HeLa, PC-3, Ishikawa, HEK-293	Concentration:	0-40 μM	Incubation Time:	48 h	Result:	Inhibited proliferation of MCF-7, MDA-MB-231, HeLa, PC-3, Ishikawa, HEK-293 cells with IC ₅₀ values of 5.45, 9.47, 22.86, 28.44, >40 and >40 μM, respectively.
Cell Line:	MCF-7, MDA-MB-231, HeLa, PC-3, Ishikawa, HEK-293								
Concentration:	0-40 μM								
Incubation Time:	48 h								
Result:	Inhibited proliferation of MCF-7, MDA-MB-231, HeLa, PC-3, Ishikawa, HEK-293 cells with IC ₅₀ values of 5.45, 9.47, 22.86, 28.44, >40 and >40 μM, respectively.								

REFERENCES

[1]. Gupta A, et al. Visible Light-Promoted Green and Sustainable Approach for One-Pot Synthesis of 4, 4'-(Arylmethylene) bis (1H-pyrazol-5-ols), In Vitro Anticancer Activity, and Molecular Docking with Covid-19 Mpro. ACS Omega, 2022.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA